Urology Nation
0 view | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Liz Ciccio
Scoop.it!

Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosi... - PubMed - NCBI

Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosi... - PubMed - NCBI | Urology Nation | Scoop.it
Clin Radiol. 2016 Oct 7. pii: S0009-9260(16)30371-3. doi: 10.1016/j.crad.2016.09.011. [Epub ahead of print]
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Yale Medicine doctors combat heartbreaking hair loss > Yale Medicine | Yale School of Medicine

more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Tips for physicians to earn secondary incomes

Tips for physicians to earn secondary incomes | Urology Nation | Scoop.it
The Medical Economics Physicians Report published earlier this year took an exclusive look at the financial state of primary care practices in the United States, including asking physicians if they received a secondary income outside their practice or employer.
But how does a physician, with a full-time practice, for example, become an expert witness, staff extra shifts in urgent care or work in telemedicine?
more...
No comment yet.
Rescooped by Liz Ciccio from Cancer Immunotherapy Review
Scoop.it!

Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early | Merck Newsroom Home

Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early | Merck Newsroom Home | Urology Nation | Scoop.it

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival. In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy. 


Based on a pre-specified interim analysis, an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped early. “The results of KEYNOTE-045 represent a major breakthrough and will be welcome news for patients dealing with previously treated advanced urothelial cancer,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “We look forward to sharing the findings from this study with the medical community and with regulatory authorities around the world.” 


 The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies involving patients with advanced urothelial cancer. Results from KEYNOTE-045 will be presented at an upcoming medical meeting.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, October 22, 9:13 AM
About KEYTRUDA ® (pembrolizumab) KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. KEYTRUDA is administered as an intravenous infusion over 30 minutes every three weeks for the approved indications. KEYTRUDA for injection is supplied in a 100 mg single use vial.

The KEYTRUDA clinical development program includes more than 30 tumor types in more than 360 clinical trials, including nearly 200 trials that combine KEYTRUDA with other cancer treatments. For genitourinary cancers, Merck has the largest immuno-oncology clinical development program in bladder cancer, with 27 trials underway involving KEYTRUDA as monotherapy and in combination, including four registration-enabling studies.
Scooped by Liz Ciccio
Scoop.it!

Relation between blood vitamin B12 levels with premature ejaculation: case-control study. - PubMed - NCBI

Relation between blood vitamin B12 levels with premature ejaculation: case-control study. - PubMed - NCBI | Urology Nation | Scoop.it
Andrologia. 2016 Sep 29. doi: 10.1111/and.12657. [Epub ahead of print]
more...
No comment yet.
Rescooped by Liz Ciccio from Cancer Immunotherapy Review
Scoop.it!

Immunotherapy: treatment of metastatic bladder cancer

Immunotherapy: treatment of metastatic bladder cancer | Urology Nation | Scoop.it
Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials.
Via Krishan Maggon
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

UAB News - Study compares treatments for urinary incontinence in women

UAB News - Study compares treatments for urinary incontinence in women | Urology Nation | Scoop.it
Patients using Botox A for urinary incontinence show higher satisfaction with treatment due to greater reduction in bothersome symptoms. Holl
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II ... - PubMed - NCBI

Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II ... - PubMed - NCBI | Urology Nation | Scoop.it
Radiother Oncol. 2016 Oct 5. pii: S0167-8140(16)34304-3. doi: 10.1016/j.radonc.2016.09.006. [Epub ahead of print]
more...
No comment yet.
Rescooped by Liz Ciccio from health care & health politics & infographics
Scoop.it!

A physician experiences a medical error. Here's her story.

A physician experiences a medical error. Here's her story. | Urology Nation | Scoop.it
Patients deserve health care without the worry of being harmed by the system itself.

Via shelbylaneMD
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Virtue male sling for post-prostatectomy stress incontinence: a prospective evaluation and mid-term outcomes. - PubMed - NCBI

Virtue male sling for post-prostatectomy stress incontinence: a prospective evaluation and mid-term outcomes. - PubMed - NCBI | Urology Nation | Scoop.it
BJU Int. 2016 Oct 3. doi: 10.1111/bju.13672. [Epub ahead of print]
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Five-year Oncologic Outcomes After Transperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma. - PubMed - NCBI

Five-year Oncologic Outcomes After Transperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma. - PubMed - NCBI | Urology Nation | Scoop.it
Eur Urol. 2016 Jun;69(6):1149-54. doi: 10.1016/j.eururo.2015.12.004. Epub 2015 Dec 22.
more...
No comment yet.
Rescooped by Liz Ciccio from Oncology Nation
Scoop.it!

An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment. - PubMed - NCBI

An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment. - PubMed - NCBI | Urology Nation | Scoop.it
Urol Int. 2016 Sep 30. [Epub ahead of print]
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

University of Colorado Cancer Center Study Shows That Double Negative Leads to Big Positive Against Bladder Cancer Metastasis

University of Colorado Cancer Center Study Shows That Double Negative Leads to Big Positive Against Bladder Cancer Metastasis | Urology Nation | Scoop.it
New understanding may allow doctors and researchers to stop bladder cancer's ability to stop the tumor-suppressing gene RhoDGI2, thus allowing its initial action to proceed.
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine. - PubMed - NCBI

Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine. - PubMed - NCBI | Urology Nation | Scoop.it
Prostate. 2016 Oct 24. doi: 10.1002/pros.23266. [Epub ahead of print]
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial

Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial | Urology Nation | Scoop.it
Cardiovascular diseases are currently the commonest cause of death worldwide. Different strategies for their primary prevention have been planned, taking into account the main known risk factors, whic
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Women report vaginal ring for preventing HIV had little effect on sexual intercourse

Violence and social harm were associated with low adherence.
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Cannabis excess linked to bone thinning | The University of Edinburgh

People who regularly smoke large amounts of cannabis have reduced bone density and are more prone to fractures, research has found.
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Robot-assisted Laparoscopic Extravesical Ureteral Reimplantation: Technique Modifications Contribute to Optimized Outcomes. - PubMed - NCBI

Robot-assisted Laparoscopic Extravesical Ureteral Reimplantation: Technique Modifications Contribute to Optimized Outcomes. - PubMed - NCBI | Urology Nation | Scoop.it
Eur Urol. 2016 Mar 29. pii: S0302-2838(16)00255-4. doi: 10.1016/j.eururo.2016.02.065. [Epub ahead of print]
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Mayo Clinic researchers map prostate cancer relapse using C-11 choline PET and MRI

Mayo Clinic researchers map prostate cancer relapse using C-11 choline PET and MRI | Urology Nation | Scoop.it
A team of Mayo Clinic researchers has, for the first time, successfully mapped patterns of prostate cancer recurrence, following surgery. Using C-11 choline PET imaging and multiparametric MRI, researchers found an anatomically diverse pattern of recurrence, which may help optimize treatment of patients whose prostate cancer returns after surgery. The research findings are published today in the Journal of Urology.
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Treatment Shrinks Bladder Cancer Tumors in Patients That Can't Tolerate Chemotherapy

Treatment Shrinks Bladder Cancer Tumors in Patients That Can't Tolerate Chemotherapy | Urology Nation | Scoop.it
NEW YORK, Oct. 10, 2016 /PRNewswire-USNewswire/ -- Treatment Shrinks Bladder Cancer Tumors in Patients That Can't Tolerate Chemotherapy.
more...
No comment yet.
Rescooped by Liz Ciccio from Endocrinologist Nation
Scoop.it!

Gene Identified that Drives Aggressive Prostate Cancer

Gene Identified that Drives Aggressive Prostate Cancer | Urology Nation | Scoop.it
An overactive gene appears to cause some prostate cancers to transform from a typical tumor type to a much more aggressive form of the disease.
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

End-Stage Renal Disease After Renal Surgery in Patients with Normal Preoperative Kidney Function: Balancing Surgical Strategy and Individual Disord... - PubMed - NCBI

End-Stage Renal Disease After Renal Surgery in Patients with Normal Preoperative Kidney Function: Balancing Surgical Strategy and Individual Disord... - PubMed - NCBI | Urology Nation | Scoop.it
Eur Urol. 2016 Mar 25. pii: S0302-2838(16)00373-0. doi: 10.1016/j.eururo.2016.03.023. [Epub ahead of print]
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Role of salvage lymph node dissection in prostate cancer. - PubMed - NCBI

Role of salvage lymph node dissection in prostate cancer. - PubMed - NCBI | Urology Nation | Scoop.it
Curr Opin Urol. 2016 Nov;26(6):581-9. doi: 10.1097/MOU.0000000000000343.
more...
No comment yet.
Scooped by Liz Ciccio
Scoop.it!

Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. - PubMed - NCBI

Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. - PubMed - NCBI | Urology Nation | Scoop.it
Eur Urol. 2016 Mar 15. pii: S0302-2838(16)00246-3. doi: 10.1016/j.eururo.2016.02.056. [Epub ahead of print]
more...
No comment yet.
Rescooped by Liz Ciccio from Dermatologist Nation
Scoop.it!

Analysis of almost 400,000 people shows that early life exposure to antibiotics is related in an increased risk of developing allergies later in life

Analysis of almost 400,000 people shows that early life exposure to antibiotics is related in an increased risk of developing allergies later in life | Urology Nation | Scoop.it
more...
No comment yet.